Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease
Open accessAbstract
Clinical PET studies using 18F-THK5351 have demonstrated significant tracer retention in sites susceptible to tau burden in Alzheimer disease (AD). However, the in vivo PET signal to reflect tau aggregates remains controversial. Methods: We examined the spatial pattern of tracer binding, amyloid-β, tau, and gliosis in an autopsy-confirmed AD patient who underwent 18F-THK5351 and 11C-Pittsburgh compound B PET before death. Results: Regional in vivo 18F-THK5351 retention was significantly correlated with the density of tau aggregates in the neocortex and monoamine oxidase-B in the whole brain, but not correlated with that of insoluble amyloid-β. Furthermore, significant association was observed between the density of tau aggregates, monoamine oxidase-B, and glial fibrillary acidic protein, suggesting that neocortical tau would strongly influence the formation of reactive astrocytes. Conclusion:18F-THK5351 PET may have limited utility as a biomarker of tau pathology in AD; however, it could be used to monitor the neuroinflammatory processes in the living brain.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
THK is known to trace not only neurofibrillary tangles but a combination of neurofibrillary tangles and astrocytosis.
“THK is known to trace not only neurofibrillary tangles but a combination of neurofibrillary tangles and astrocytosis (Ng et al., 2017; Harada et al., 2018).”
From Effects of Alzheimer’s and Vascular Pathologies on Structural Connectivity in Early- and Late-Onset Alzheimer’s Disease (2021) · cites this paper as Harada et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · see citing works
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · see citing works
Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488 · see citing works
Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442 · see citing works
Marutle, A., Gillberg, P.-G., Bergfors, A., Yu, W., Ni, R., Nennesmo, I., Voytenko, L., & Nordberg, A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-90 · Cited by 70 · see citing works
Flagged first, then by citations
Research works printed but not linked: 10
- Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14:500.
- Villemagne VL, Dore V, Bourgeat P, et al. Ab-amyloid and tau imaging in dementia. Semin Nucl Med. 2017;47:75-88.
- Harada R, Okamura N, Furumoto S, et al. 18 F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57: 208-214.
- Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25.
- Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain mono- amine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431- 435.
- Tong J, Meyer JH, Furukawa Y, et al. Distribution of monoamine oxidase pro- teins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2013;33:863-871.
- Saura J, Luque JM, Cesura AM, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative en- zyme radioautography. Neuroscience. 1994;62:15-30.
- Gulya ´s B, Pavlova E, Kasa P, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [ 11 C]-L-deprenyl using whole hemisphere autoradiog- raphy. Neurochem Int. 2011;58:60-68.
- Santillo AF, Gambini JP, Lannfelt L, et al. In vivo imaging of astrocytosis in Alzheimer's disease: an 11 C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging. 2011;38:2202-2208.
- Ingelsson M, Fukumoto H, Newell KL, et al. Early Ab accumulation and pro- gressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925-931.
Cited by
Sorted by citations
Tau-positron emission tomography correlates with neuropathology findings.
Lowe, V. J., Lundt, E. S., Albertson, S. M., Min, H., Fang, P., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Kantarci, K., Boeve, B., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.079 · Cited by 203 · see citing works
Yokoi, T., Watanabe, H., Yamaguchi, H., Bagarinao, E., Masuda, M., Imai, K., Ogura, A., Ohdake, R., Kawabata, K., Hara, K., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00304 · Cited by 116 · see citing works
Self-citationNakaya, M., Sato, N., Matsuda, H., Maikusa, N., Shigemoto, Y., Sone, D., Yamao, T., Ogawa, M., Kimura, Y., Chiba, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12356 · Cited by 41 · see citing works
Self-citationLee, W. J., Yoon, C. W., Kim, S.-W., Jeong, H. J., Seo, S., Na, D. L., Noh, Y., & Seong, J.-K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.606600 · Cited by 12 · see citing works
Strobel, J., Müller, H.-P., Ludolph, A. C., Beer, A. J., Sollmann, N., & Kassubek, J. (2023) · Cells · doi:10.3390/cells12242776 · Cited by 10 · see citing works
- Authors
- Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., Tago, T., Tomita, N., Watanuki, S., Hiraoka, K., Ishikawa, Y., Funaki, Y., Nakamura, T., Yoshikawa, T., Iwata, R., Tashiro, M., Sasano, H., Kitamoto, T., Yanai, K., Arai, H., Kudo, Y., & Okamura, N.
- Affiliations
- Tohoku University (JP)
- Tokyo Metropolitan Institute of Gerontology (JP)
- Tohoku Medical and Pharmaceutical University (JP)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-09-01
- Volume
- 59
- Issue
- 4
- Pages
- 671-674
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2750990748
- Cited by
- 168
- References
- 5
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 12 · 2023: 20 · 2022: 14 · 2021: 20 · 2020: 35 · 2019: 24 · 2018: 24 · 2017: 2
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K08127, 16H07486, 16H05383, 26253016)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 18F-THK5351, tau PET imaging, Alzheimer's disease, tau pathology, astrocyte activation, reactive astrocytes, amyloid-beta, monoamine oxidase B, glial fibrillary acidic protein, neuroinflammation, biomarkers, neocortex
- MeSH terms
- Aged, 80 and over, Alzheimer Disease, Aminopyridines, Gliosis, Humans, Male, Postmortem Changes, Quinolines, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
